Association of Middle Molecules Clearance and Clinical Parameters With Haemodiafiltration Convection Volume

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

HDF is a dialysis technique which involves diffusion and convection. HDF with high convection volume has consistently shown to improve survival in dialysis patients in number of robust RCTs. The precise reason of this survival benefit remains unclear. The investigators hypothesize that this survival benefit with high volume HDF is related to enhanced middle molecule clearance and hemodynamic stability. However, this relationship has not been studied so far. This observational study is aimed to understand the relationship between HDF convection volume with middle molecules (Beta 2-Microglobulin) clearance during HDF. Exploring the relationship of HDF volume with middle molecules clearance has significant clinical ramifications. Only a minority of patients are able to achieve target convection volume. Understanding these relationships can rationalize the HDF prescription from convection volume-based prescription to β2-Microglobulin clearance-based prescription which may be applicable to wider range of patients. The relationship between pre-dialysis β2-Microglobulin levels and RKF offers the prospect of dispensing with pre- and post-dialysis urea and creatinine measurements and interdialytic urine collections, currently necessary for estimating RKF, thus simplifying its estimation. β2-Microglobulin reduction ratio and its component pre and post-dialysis β2-Microglobulin levels could therefore provide a composite estimate of small and middle molecule clearance and RKF.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or above.

• Ability to give informed consent.

• End stage renal failure treated by dialysis for at least 3 months.

• Established on hemodiafiltration for \>4 weeks.

• Prognosis more than 6 months as assessed by PI

Locations
Other Locations
United Kingdom
East and North Hertfordshire NHS Trust
RECRUITING
Stevenage
Contact Information
Primary
Usama A Butt, MBBS,MRCP
usama.butt1@nhs.net
+441438284340
Time Frame
Start Date: 2024-01-19
Estimated Completion Date: 2025-07
Participants
Target number of participants: 400
Treatments
HDF patients
ESRF patients who are receiving renal replacement therapy in the form of HDF
Related Therapeutic Areas
Sponsors
Leads: East and North Hertfordshire NHS Trust

This content was sourced from clinicaltrials.gov